Compare Natera Inc. Common Stock (NTRA) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Upstart Holdings Inc — how do they compare? Natera Inc. Common Stock trades at $392.22 (market cap $57.03B), while Upstart Holdings Inc trades at $22.6 (market cap $2.32B). The key difference: Natera Inc. Common Stock is far larger — about 24.6× Upstart Holdings Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Upstart Holdings Inc for 39 Days on average.
| NTRA | UPST | |
|---|---|---|
Market Cap | $57.03B | $2.32B |
Volume | 1,131,157 | 3,123,987 |
Sector | Health | Financials |
52-Week High | $425.64 | $52.74 |
52-Week Low | $179.42 | $22.74 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $56.18B | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
UPST trades at $22.74, down 4.25% on the day, with a bearish technical signal and recent earnings misses. Revenue grew to $1.02B in 2025, turning profitable with $53.60M net income, but cash flow from operations remains negative. The stock is trading well below the consensus price target of $38.13, with analysts divided between Buy and Hold ratings.
The outlook is mixed: strong revenue growth and profitability improvements offer upside potential, but persistent cash burn, high debt levels, and sensitivity to credit markets pose significant risks. Investor sentiment is cautious amid recent price declines and sector-wide pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
